Compare CRSP & MHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | MHK |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.9B |
| IPO Year | 2016 | 1995 |
| Metric | CRSP | MHK |
|---|---|---|
| Price | $50.21 | $102.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 11 |
| Target Price | $70.29 | ★ $126.10 |
| AVG Volume (30 Days) | ★ 1.7M | 950.3K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.90 |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $807.72 | $3.38 |
| Revenue Next Year | $172.52 | $3.09 |
| P/E Ratio | ★ N/A | $53.75 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $35.38 | $92.99 |
| 52 Week High | $78.48 | $143.13 |
| Indicator | CRSP | MHK |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 51.74 |
| Support Level | $44.82 | $94.44 |
| Resistance Level | $60.45 | $107.39 |
| Average True Range (ATR) | 2.49 | 3.76 |
| MACD | -0.37 | 0.30 |
| Stochastic Oscillator | 35.44 | 66.06 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Global Ceramic designs, manufactures, sources, distributes and markets a broad line of ceramic, porcelain and natural stone tile products used for floor and wall applications in residential and commercial channels for both remodeling and new construction. Geographically, it derives a majority of its revenue from the United States, while it also operates in Latin America, Europe and Others.